Comparative Study Between Levobupivacaine and Bupivacaine for Nerve Block During Pediatric Primary Cleft Palate Surgery

Model scores of the 29,894 trials active now.

Model score 12% for any early termination, 3% for termination due to slow enrollment. Past trials like this one (phase and sponsor type, started 2008–2016) ended terminated 13% of the time (1,012 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2016-10-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: injurycareassociatedblockthe risk
  Phrases that lowered it: nasalgoodgeneraluppercombination
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Primary purpose: prevention (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 87 (lowers risk) · Sponsor's track record
• Responsible party: principal investigator (lowers risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Drug's FAERS reports with a death: 8.9% (lowers risk) · Drug's FDA history
• Minimum age: 1 (lowers risk) · Who can join
• Design: parallel (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Phase: 2/3 (raises risk) · Design
• Number of arms: 2 (raises risk) · Design
• Blinding: double (raises risk) · Design
• Drug's FAERS reports before start: 5095 (raises risk) · Drug's FDA history
• Drug's FAERS reports marked serious: 88.3% (raises risk) · Drug's FDA history
• Maximum age: 10 (raises risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Suprazygomatic Block in Cleft Palate Surgery in Children NCT03412474 · started 2018 · scored riskier than 10% of active trials completed
• Infra-orbital Nerve Block for Post Operative Analgesia in Children Undergoing Cleft Lip Surgery. NCT02514980 · started 2015 · scored riskier than 11% of active trials completed
• Nalbuphine as Adjuvant During Bilateral Suprazygomatic Maxillary Nerve Block for Pediatric Cleft Palate Repair NCT06100315 · started 2023 · scored riskier than 4% of active trials completed
• Does it Worth to Reinforce With Additional Anesthesia to Improve Postoperative Course After Orthognathic Surgery? NCT03974035 · started 2018 · scored riskier than 19% of active trials completed
• Dexmedetomidine Versus Magnesium Sulphate Added to Bupivacaine in Infraorbital Nerve Block for Perioperative Analgesia in Paediatric Patients for Cleft Lip Surgery NCT05624151 · started 2022 · scored riskier than 11% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.